Global Markets Direct’s, ‘Tardive Dyskinesia - Pipeline Review, H2 2015’, provides an overview of the Tardive Dyskinesia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Tardive Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tardive Dyskinesia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Tardive Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tardive Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tardive Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tardive Dyskinesia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Tardive Dyskinesia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Tardive Dyskinesia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Our reports have been used by over 10K customers, including:
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2018 Summary Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via...
110 pages •
By Infiniti Research Limited
• Nov 2018
About Peanut Allergy Peanut allergy is one of the most common types of food allergies that results in itchiness, abdominal pain, swelling, sneezing, diarrhea, and cardiac arrest. Technavio’s analysts forecast the Global Peanut Allergy Market to grow at a CAGR of 89.68% during the period 2019-2023. Covered...
Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2018 Summary Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular...
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 188.8.131.52 or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary According to the recently published report ’Cytochrome P450 11B2 Mitochondrial - Pipeline...
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 220.127.116.11) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 18.104.22.168) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining...